<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362169">
  <stage>Registered</stage>
  <submitdate>26/03/2012</submitdate>
  <approvaldate>30/03/2012</approvaldate>
  <actrnumber>ACTRN12612000368831</actrnumber>
  <trial_identification>
    <studytitle>GIVE UP FOR GOOD- A study to evaluate the effectiveness of a pharmacist-led multidisciplinary smoking cessation intervention for smokers admitted to public hospitals.</studytitle>
    <scientifictitle>A multi-centre, randomized, controlled study to evaluate the effectiveness of pharmacist-led multidisciplinary system-change smoking cessation intervention in comparison with usual care for smokers admitted to public hospitals.</scientifictitle>
    <utrn>U1111-1128-6290</utrn>
    <trialacronym>GIVE UP FOR GOOD</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Tobacco use and dependence</healthcondition>
    <healthcondition>Smoking Cessation</healthcondition>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Health service research</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants randomized to intervention arm will receive a series of smoking cessation counselling sessions by a specially trained pharmacist over the course of at least three sessions: the first during hospital stay, second on discharge or immediately after discharge and third within one month post-discharge. Each participant will be counselled individually and each counselling session will take approximately 15 minutes. All smoking cessation medications during hospital stay and for at least one week after discharge will be provided free of charge. When participants are discharged from hospital, the pharmacist will communicate with participant's General Practitioner and community pharmacist about further smoking cessation support.</interventions>
    <comparator>Control group will receive the current standard care provided by the hospital. Current policy  at each participating hospital includes brief (up to 5 mins) advice and /or pharmacotherapy provided by hospital staff as part of usual care to all inpatients who are smokers.</comparator>
    <control>Active</control>
    <interventioncode>Lifestyle</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Carbon Monoxide (CO) validated 7-day point prevalence abstinence</outcome>
      <timepoint>6 months and 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Continuous abstinence will be assessed using patient self report during interviews.</outcome>
      <timepoint>1 month, 6 months and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>24hr/7-day/30-day point prevalence abstinence will be assessed using patient self report during interviews.</outcome>
      <timepoint>1 month, 6 months and 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age 18 years and above, who are smokers at the time of hospital admission and available for follow-up on discharge, and at 1, 6, and 12 months post-discharge</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Physical or mental inability to participate in the study, unable to provide written informed consent, unable to communicate in English, terminal illness, pregnancy and on another smoking cessation therapy or program at the time of hospital admission</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelope method.</concealment>
    <sequence>Stratified block randomisation - Participants will be stratified based on Heaviness of Smoking Index -Light Smokers and Heavy smokers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/04/2012</anticipatedstartdate>
    <actualstartdate>2/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>6/06/2013</actualenddate>
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>381 Royal Parade
Parkville
Victoria 3052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian Research Council</fundingname>
      <fundingaddress>Level 2, 11 Lancaster Place
Majura Park ACT 2609</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Australia Pty Ltd</fundingname>
      <fundingaddress>38-42 Wharf Road
West Ryde NSW 2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>The University of Newcastle</othercollaboratorname>
      <othercollaboratoraddress>Cnr King and Auckland Streets
Newcastle NSW 2300</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>The Alfred</othercollaboratorname>
      <othercollaboratoraddress>Commercial Road,
Melbourne. VIC 3004</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Austin Hospital</othercollaboratorname>
      <othercollaboratoraddress>145 Studley Road     
Heidelberg
VIC 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Barwon Health</othercollaboratorname>
      <othercollaboratoraddress>The Geelong Hospital
Bellerine Street 
Geelong VIC 3220</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>"GIVE UP FOR GOOD" (Copyright) is a research study, evaluating the effectiveness of a pharmacist-led multidisciplinary system change smoking cessation intervention for smokers admitted to Victorian hospitals. Approximately 200 smokers will be recruited from each of three participating Victorian hospitals (The Alfred, Austin Health &amp; Barwon Health). Participants will have an equal chance of being randomly allocated to either the intervention or usual care (control) group.

Participants randomized to "Give up for Good" program will receive a series of smoking cessation counseling sessions by a specially trained pharmacist over the course of at least three sessions. The first during the hospital stay, second on discharge or immediately after the discharge and third within one month post-discharge. All smoking cessation medications during the hospital stay and for at least one week after discharge will be provided free of charge. When participants are discharged from hospital, the pharmacist will communicate with the participant's General Practitioner and community pharmacist about further smoking cessation support. Participants randomized to usual care group receive the current routine care provided by the hospital. 

All the participants will be followed up for a period of 12 months. All measurements at baseline, discharge, 1 month, 6 months and 12 months will be performed by a Research Assistant blinded to group allocation. The main outcome measures are abstinence from smoking on discharge, and 1 month, 6 months and 12 months post-discharge.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Ethics Committee</ethicname>
      <ethicaddress>The Alfred Hospital
55 Commercial Road
Melbourne
Victoria 3004</ethicaddress>
      <ethicapprovaldate>2/03/2012</ethicapprovaldate>
      <hrec>314/11</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Ethics Unit
Henry Buck Building
Austin Hospital</ethicaddress>
      <ethicapprovaldate>7/02/2012</ethicapprovaldate>
      <hrec>H2011/04438</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Barwon Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Barwon Health 
Ryrie Street 
Geelong</ethicaddress>
      <ethicapprovaldate>24/01/2012</ethicapprovaldate>
      <hrec>11/91</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Johnson George</name>
      <address>Faculty of Pharmacy and Pharmaceutical Sciences
Centre for Medicine Use and Safety
Monash University (Parkville Campus)
381 Royal Parade, Parkville
VIC 3052</address>
      <phone>+61-3-9903 9178</phone>
      <fax>+61-3-9903 9629</fax>
      <email>johnson.george@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Johnson George</name>
      <address>Faculty of Pharmacy and Pharmaceutical Sciences
Centre for Medicine Use and Safety
Monash University (Parkville Campus)
381 Royal Parade, Parkville
VIC 3052</address>
      <phone>+61-3-9903 9178</phone>
      <fax>+61-3-9903 9629</fax>
      <email>johnson.george@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr. Dennis Thomas</name>
      <address>Faculty of Pharmacy and Pharmaceutical Sciences
Centre for Medicine Use and Safety
Monash University (Parkville Campus)
381 Royal Parade, Parkville
VIC 3052</address>
      <phone>+61-3-99039025</phone>
      <fax />
      <email>dennis.thomas@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Johnson George </name>
      <address>Faculty of Pharmacy and Pharmaceutical Sciences 
Centre for Medicine Use and Safety 
Monash University (Parkville Campus) 
381 Royal Parade, 
Parkville 
VIC 3052 </address>
      <phone>+61-3-9903 9178 </phone>
      <fax />
      <email>johnson.george@monash.edu </email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>